exemestane (Aromasin)

05/01/2000 - "Exemestane is a unique therapy that is highly active and well tolerated as a new treatment for women with metastatic breast cancer."
02/10/2003 - "An effective hormonal medicine, exemestane has good therapeutic efficacy in postmenopausal advanced metastatic breast cancer with only mild side effects."
06/20/2013 - "Regarding current evidence and related costs in terms of Iranian pharmaceutical market prices, exemestane could not be considered a cost-effective treatment in primary and advanced breast cancer compared with available alternatives. "
04/01/2009 - "Neo-adjuvant exemestane given for 6 months appears to be effective for receptor-rich breast cancer in older patients. "
01/01/2009 - "Available data, some of which are limited, suggest exemestane is also effective in the first-line hormonal treatment of advanced breast cancer in postmenopausal women. "

03/01/2005 - "Exemestane given at 25 mg/day markedly improved both clinical symptoms and tumor marker levels. "
02/01/2015 - "Tregs and the tumor IS presented in this study harbor prognostic value for sequentially endocrine-treated HR+ve postmenopausal BC patients, but not for solely exemestane-treated patients. "
06/01/2013 - "The placebo-controlled phase III MAP.3 trial tested the AI exemestane in high-risk women and documented a 65% relative reduction in total and a 73% reduction in ER-positive breast cancers in the intervention compared to the placebo group. "
01/01/2008 - "The present study points to apparent tumor - promoting effects of dietary administered exemestane in the model of premenopausal mammary carcinogenesis in female rats. "
01/01/2013 - "Microbial transformation of anti-cancer steroid, exemestane (1), was investigated by using two filamentous fungi. "

04/01/2011 - "The clinical benefit for exemestane (SAI) after any NSAI failure or before treatment ranged from 12% (complete response not recorded, partial response 2%, stable disease 10%) to 55% (complete response 6%, partial response 13%, stable disease 35%) Survival outcomes were infrequently reported; four studies reported disease progression. "
11/01/2014 - "On exemestane, disease progression was documented in five patients, with one having stable disease as best response. "
09/01/2014 - "Nevertheless, some patients still experience disease progression under exemestane. "
03/01/2013 - "All patients received 25 mg exemestane daily until objective disease progression. "
02/01/2004 - "After a period of disease stabilization and subsequent disease progression in the right supraclavicular fossa, Exemestane was discontinued. "

07/01/2015 - "Recent large phase III clinical trials, including the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG-12), Suppression of Ovarian Function Trial (SOFT), and Tamoxifen and Exemestane Trial (TEXT), did not demonstrate an improvement in disease-free survival with ovarian suppression in the overall population. "
01/01/2008 - "A smaller open-label trial, the Austrian Breast and Colorectal Cancer Study Group 6a has reported a significant benefit for anastrozole on recurrence when used as extended adjuvant therapy when compared with no treatment, and similar results have been seen with extended adjuvant exemestane in the National Surgical Adjuvant Breast and Bowel Project B-33 trial. "
08/01/2007 - "Recent data on the NSABP B-33 trial, which investigated exemestane in the extended adjuvant setting, and Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 6a, which evaluated anastrozole in the extended adjuvant setting, have also been reported. "
11/01/2008 - "Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)."
02/01/2008 - "These studies were designed to evaluate the safety and efficacy of AIs in the following clinical settings: 1) as initial adjuvant therapy (the Arimidex, Tamoxifen, Alone or in Combination trial, Breast International Group Trial 1-98), 2) in a "switched setting" after 2 to 3 years of treatment with tamoxifen (Arimidex-Nolvadex 95, the Austrian Breast and Colorectal Cancer Study Group 8 [ABCSG 8] trial, the Italian Tamoxifen Anastrozole study, the Intergroup Exemestane Study), and 3) in extended settings (National Cancer Institute of Canada Trial MA.17, ABCSG 6a, National Surgical Adjuvant Breast and Bowel Project 33). "

01/01/2014 - "After 3 months of exemestane, CT showed that all lung metastases had completely resolved. "
06/01/2001 - "Response rates to exemestane of 14% to 29% were observed including patients with visceral metastases, who have historically proven difficult to treat. "
05/01/2009 - "[A case of recurrent breast cancer with liver metastasis responding to exemestane]."
09/01/2005 - "Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer."
10/01/2004 - "[A case of aged advanced breast cancer with multiple lung and pleural metastases responding to exemestane monotherapy]."